Atlas (Atlas Genetics Ltd) develops ultra-rapid point-of-care (POC) diagnostic tests for infectious diseases. The Atlas io™ system uses patented technology based on the use of a novel electrochemical sensor that combines speed, accuracy and multiplex detection capability. The Company has its head office and laboratory facilities near Bath. Atlas was established in 2005 and is financed by VC, corporate and private investors including Consort Medical plc, Novartis Venture Funds, J&J Development Corporation, Life Science Partners (LSP), BB Biotech Ventures and YFM Equity Partners. The company raised £16.9 million in series B finance in 2011.
The Atlas io™ platform
POC diagnostics offer health professionals the ability to test for medical conditions at the site of patient care. Atlas has developed the io™ system, a flexible POC technology platform, which has been designed to accurately and quickly diagnose a wide range of medical conditions within 30 minutes. The Atlas io™ system consists of an inexpensive test machine into which a disposable cartridge containing a patient sample is inserted. The io™ platform is scheduled for clinical trials in 2014, followed by rollout in Europe and the United States, pending regulatory approvals.
Atlas is developing tests for a range of infectious diseases including sexually transmitted infections and hospital acquired infections. The io™ system will initially be launched for the rapid testing of Chlamydia, allowing clinicians to test and treat patients in a single visit. Around 40 million tests are carried out for these diseases in Europe and the US every year. According to the European Centre for Disease Prevention and Control, Chlamydia is the most frequently reporte
|SOURCE Atlas Genetics Ltd.|
Copyright©2012 PR Newswire.
All rights reserved